CD73 Promotes Chronic Lymphocytic Leukemia.

Area of Science:

• Immunology
• Oncology
• Biochemistry

Background:

• CD73 (ecto-nucleotidase) is a key immune checkpoint, converting extracellular ATP to adenosine.
• CD73's role in solid tumors is known, but its function in leukemia is unclear.
• Adenosine signaling suppresses anti-tumor immunity.

Purpose of the Study:

• To investigate the role of CD73 in the pathogenesis of chronic lymphocytic leukemia (CLL).
• To determine the impact of CD73 deficiency on CLL progression and survival.
• To explore potential sex-based differences in CD73's role in CLL.

Main Methods:

• Eµ-TCL1 transgenic mice (spontaneously develop CLL) were crossed with CD73-deficient mice.
• Flow cytometry was used to evaluate disease progression, CLL markers, and T cell populations (IFN-γ+, CD8+ effector-memory).
• In vitro studies assessed adenosine signaling and PD-L1 expression; genomic analysis of human CLL samples was performed.

Main Results:

• CD73 deficiency significantly delayed CLL progression and prolonged survival in male Eµ-TCL1 mice.
• This survival advantage was linked to increased IFN-γ+ T cells and effector-memory CD8+ T cells, and was abrogated by IFN-γ neutralization.
• In female mice, CD73 deficiency correlated with CD39 upregulation and sustained PD-L1 expression on CLL cells, while in vitro studies confirmed adenosine signaling enhances PD-L1.

Conclusions:

• CD73 acts as a pro-leukemic immune checkpoint in CLL, promoting disease progression.
• CD73 deficiency confers a survival benefit in male mice via enhanced T cell immunity.
• A significant sex bias exists in the CD73-adenosine pathway's impact on CLL, with implications for therapeutic strategies.